221 related articles for article (PubMed ID: 35488033)
21. Developing a 3D B Cell Lymphoma Culture System to Model Antibody Therapy.
Foxall R; Narang P; Glaysher B; Hub E; Teal E; Coles MC; Ashton-Key M; Beers SA; Cragg MS
Front Immunol; 2020; 11():605231. PubMed ID: 33628205
[TBL] [Abstract][Full Text] [Related]
22. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
[No Abstract] [Full Text] [Related]
23. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
[TBL] [Abstract][Full Text] [Related]
24. Mutations of the 5' noncoding region of the BCL-6 gene in primary bone lymphomas.
Gianelli U; Ponzoni M; Moro A; Alfano RM; Pellegrini C; Giardini R; Patriarca C; Armiraglio E; Bosari S; Parafioriti A; Coggi G
Ann Hematol; 2003 Nov; 82(11):691-5. PubMed ID: 14513282
[TBL] [Abstract][Full Text] [Related]
25. Burkitt lymphoma (BL): reclassification of 39 lymphomas diagnosed as BL or Burkitt-like lymphoma in the past based on immunohistochemistry and fluorescence in situ hybridization.
Kodet R; Mrhalová M; Stejskalová E; Kabícková E
Cesk Patol; 2011 Jul; 47(3):106-14. PubMed ID: 21887927
[TBL] [Abstract][Full Text] [Related]
26. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.
Wang ES; O'Connor O; She Y; Zelenetz AD; Sirotnak FM; Moore MA
Leuk Lymphoma; 2003 Jun; 44(6):1027-35. PubMed ID: 12854905
[TBL] [Abstract][Full Text] [Related]
27. Cytotoxic protein expression in natural killer cell lymphomas and in alpha beta and gamma delta peripheral T-cell lymphomas.
Boulland ML; Kanavaros P; Wechsler J; Casiraghi O; Gaulard P
J Pathol; 1997 Dec; 183(4):432-9. PubMed ID: 9496260
[TBL] [Abstract][Full Text] [Related]
28. Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt lymphoma and high-grade B-cell lymphoma.
Graef CM; Gödel P; Falderbaum P; Balke-Want H; Simon F; Sieg N; Naendrup JH; Neumann MA; Gillessen S; Bröckelmann PJ; Eichenauer DA; Borchmann P; von Tresckow B; Heger JM
Eur J Haematol; 2022 May; 108(5):403-412. PubMed ID: 35090068
[TBL] [Abstract][Full Text] [Related]
29. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
30. Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research.
Kawaguchi T; Foster BA; Young J; Takabe K
J Mammary Gland Biol Neoplasia; 2017 Jun; 22(2):131-139. PubMed ID: 28451789
[TBL] [Abstract][Full Text] [Related]
31. Complexities in the diagnosis of large B-cell lymphomas, classic Hodgkin lymphomas and overlapping peripheral T-cell lymphomas simplified: An evidence-based guide.
Wen KW; Fakhri B; Menke J; Ruiz-Cordero R; Gill RM; Ohgami RS
Ann Diagn Pathol; 2020 Jun; 46():151534. PubMed ID: 32473554
[TBL] [Abstract][Full Text] [Related]
32. [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis].
Tagawa H
Gan To Kagaku Ryoho; 2007 Jul; 34(7):975-82. PubMed ID: 17637530
[TBL] [Abstract][Full Text] [Related]
33. Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance.
Fisher KE; Ferguson LS; Coffey AM; Merritt BY; Curry JL; Marcogliese AN; Major AM; Kamdar KY; Lopez-Terrada DH; Curry CV
Haematologica; 2022 Aug; 107(8):1880-1890. PubMed ID: 35081690
[TBL] [Abstract][Full Text] [Related]
34. Establishment and genetically characterization of patient-derived xenograft models of cervical cancer.
Zou S; Ye M; Zhang JA; Ji H; Chen Y; Zhu X
BMC Med Genomics; 2022 Sep; 15(1):191. PubMed ID: 36076209
[TBL] [Abstract][Full Text] [Related]
35. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?
Bladergroen BA; Meijer CJ; ten Berge RL; Hack CE; Muris JJ; Dukers DF; Chott A; Kazama Y; Oudejans JJ; van Berkum O; Kummer JA
Blood; 2002 Jan; 99(1):232-7. PubMed ID: 11756176
[TBL] [Abstract][Full Text] [Related]
36. CXCR5
Tang J; Zha J; Guo X; Shi P; Xu B
Int Immunopharmacol; 2017 Sep; 50():146-151. PubMed ID: 28662433
[TBL] [Abstract][Full Text] [Related]
37. The challenge of the microenvironment in B-cell lymphomas.
Coupland SE
Histopathology; 2011 Jan; 58(1):69-80. PubMed ID: 21261684
[TBL] [Abstract][Full Text] [Related]
38. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
[TBL] [Abstract][Full Text] [Related]
39. Perforin and granzyme expression in cytotoxic T-cell lymphomas.
Yamashita Y; Yatabe Y; Tsuzuki T; Nakayama A; Hasegawa Y; Kojima H; Nagasawa T; Mori N
Mod Pathol; 1998 Apr; 11(4):313-23. PubMed ID: 9578080
[TBL] [Abstract][Full Text] [Related]
40. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
Kubuschok B; Trepel M
Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]